Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

NCT02601014 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer
Recurrent Prostate Carcinoma
Stage IV Prostate Adenocarcinoma

Interventions

BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab
DRUG: Enzalutamide

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]